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Abstract
The simultaneous measurement of different substances from a single sample is 
an emerging area for achieving efficient and high-throughput detection in several 
applications. Although immunoanalytical techniques are established and advanta-
geous over alternative screening analytical platforms, one of the challenges for 
immunoassays is multiplexing. While ELISA is still commonly used to characterise a 
single analyte, laboratories and organisations are moving towards multiplex immu-
noassays. The validation of novel biomarkers and their amalgamation into multi-
plex immunoassays confers the prospects of simultaneous measurement of multiple 
analytes in a single sample, thereby minimising cost, time and sample. Therefore, 
the technological advancement in clinical sciences is helpful in the identification 
of analytes or biomarkers in test samples. However, the analytical bioanalysers are 
expensive and capable of detecting only a small amount or type of analytes. The 
simultaneous measurement of different substances from a single sample called mul-
tiplexing has become increasingly important for the quantification of pathological 
or toxicological samples. Although multiplex assays have many advantages over 
conventional assays, there are also problems that may cause apprehension among 
clinicians and researchers. Hence, many challenges still remain for these multiplex-
ing systems which are at early stages of development.
Keywords: biomarkers, multiplex assays, immunoassays, autoantibodies, ELISA, 
analytes
1. Introduction
An early and accurate diagnosis of a specific disease plays an important role in 
its effective treatment, especially in an emergency where an immediate decision 
needs to be made (such as in stroke or sepsis) for the treatment of patient, and the 
rapid and precise identification of the pathological condition is vital. However, in 
many instances, the clinical evidence based on a single analyte or biomarker is not 
adequate for an appropriate diagnosis of a disease or monitoring of its treatment. 
The biomarkers have a pathophysiological significance and clinical application 
which may have a profound impact on the diagnosis and treatment of the patient. 
While contemporary singleplex techniques such as enzyme-linked immunosorbent 
assay (ELISA) and biomarker kits are able to accurately analyse a single analyte, the 
monitoring of more complex, multifactorial diseases such as cancer and autoim-
mune and neurodegenerative diseases requires the analysis of multiple biomarkers 
in order to implement optimised therapeutic regimen [1]. In addition, it is advan-
tageous to screen various analytes simultaneously for a rapid, cost-effective and 
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reliable quantification [2, 3]. The development of technologies for the analysis of 
whole genome (genomic) and total proteins (proteomic) has ushered in a new era 
of biomarker discovery, which has yielded numerous new biomarkers. In the future, 
they will have a significant impact on clinical diagnostics and therapeutics [2]. Since 
the advent of the proteomic era, multiplex immunoassays now constitute valu-
able tools for efficiently harnessing information available to expedite observation, 
monitoring and treatment of diseases. While the availability and implementation of 
commercial multiplex immunoassays for research applications is expanding rapidly, 
incorporation of the technology within routine clinical diagnostics is in infancy due 
to operational and quality control issues such as robust automation, time constraint, 
operational cost, etc. [1]. The multiplex assays are now replacing conventional 
ELISAs to save time, material and labour costs and allow efficient handling of a 
large number of samples to enhance the overall throughput. With increasing run-
ning costs, a major focus of immunoassays has shifted towards cost-effectiveness 
and convenience of handling a large number of samples rather than results and 
reliability of the assay.
Most of the diagnostic methods rely on immunoassays or enzymatic reactions 
and strongly depend on the sample (e.g. size of sample, patient-to-patient varia-
tion) and assay conditions (e.g. temperature, humidity, etc.) [3]. An ideal device 
for emergency testing should offer high performance, sensitivity, multiplexing 
capability, short turnaround time, low system complexity, low-cost fabrication and 
minimised user intervention [3]. Therefore, the multiplexed diagnostic devices 
capable of high-throughput analysis of several parameters have recently become 
important in the last couple of decades which are able to analyse different markers 
simultaneously, e.g. RNAs, metabolites, proteins, cells, etc. [3]. Multiplex immu-
noassays confer several advantages over widely used singleplex assays including 
increased efficiency, greater output per sample volume and higher throughput 
prediction leading to detailed diagnosis facilitating personalised medicine. 
Nonetheless, relatively few protein multiplex immunoassays have been validated 
for in vitro diagnostics in clinical settings ([1]). The emerging need and demand 
for novel biomarkers (e.g. aptamers) or targets (e.g. circulating RNAs and DNA, 
tumour cells, miRNAs, etc.) and their applications for diagnostic, prognostic 
and therapeutic implications, including therapeutic drug monitoring, will shape 
the future of multiplex systems [3]. The validation of novel biomarkers and their 
incorporation into multiplex immunoassays confers the prospect of simultaneous 
measurement of multiple analytes in a single patient sample, thereby minimising 
assay costs, time and sample volume. Moreover, the advent of multiplex technology 
complements the progressive shift towards personalised medicine with holistic, 
molecular analyses of diseases through the identification and characterisation of 
biomarkers to accommodate greater diagnostic resolution between closely related 
disease phenotypes. The multiplex immunoassays will continue to garner popular-
ity and secure a mainstream role in research and eventually clinical settings [1].
The singleplex or conventional ELISA immunoassays have assumed a ‘work-
horse’ role in the highly sensitive qualitative and quantitative detection of analytes 
within heterogeneous samples for over half a century. Moreover, the advent of 
hybridoma technology as a means of generating monoclonal antibodies (MAbs) has 
facilitated the generation of highly robust, antibody-based assays for standardisa-
tion and automation [4]. Both the singleplex and multiplex ELISAs adopt a common 
‘sandwich’ format (capture antibody-analyte-detection antibody). The multiplex 
ELISA adopts chemiluminescent/fluorescent reporter systems as enzymatic report-
ers are chemically incompatible for simultaneous analysis of multiple localised 
targets. The concept of immunoassay for diagnostics was conceived in 1963 by 
Joseph G. Feinberg and A.W. Wheeler when they developed a ‘microspot’ technique 
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as a means of detecting autoimmune antibody and tissue antigens, whereby thyro-
globulin immobilised in a microspot on cellulose acetate strips were incubated with 
serum from autoimmune thyroiditis patients [5]. The microspot assay has the ability 
to detect low levels of both autoantibody and antigen; has the advantage of being 
simple, sensitive, objective and quick; and requires minute quantities of serum and 
antigen. In 1989, Ekins postulated the miniaturisation of immunoassays (i.e. reduc-
tion of the capture antibody concentration) and outlined the fundamental microar-
ray multiplex technology principles and envisioned their potential application in 
research and clinical diagnostics [6]. The large-scale screening in the postgenomic 
era has encompassed applications, ranging from functional analysis of unknown 
genes to identification of disease-related gene products, screening in drug discovery 
and clinical diagnostics [1].
2. Principle of multiplex assays
The multiplex assays require complex technology such as PCR, ELISA, microar-
rays, gel electrophoresis, capillary electrophoresis, Sanger sequencing, etc. The 
fluorescence spectroscopy measurements are important due to its compatibility 
with biochemical assays, small size of sample, ease of conjugation to potential mol-
ecules, affordability, stability, robustness and detection with less expensive optical 
instruments [7]. Mass spectrometry (MS) can identify molecules without separa-
tion. For example, matrix-assisted laser desorption/ionisation mass spectrometry 
(MALDI-MS) is employed in hospitals to characterise antigens [1]. However, these 
bioanalysers are bulky, expensive and capable of detecting only a small amount or 
type of analyte [1]. Thus, there are still many challenges of these systems due to 
their cost or their detection capability [1, 2].
Multiplexing as a new technology emerged a few decades ago for the detection 
and quantification of first nucleic acids and then proteins. Using this technology, 
a range of biomarker molecules can be identified and quantified for health and 
disease. Multiplexing is a significant technology for the analysis of thousands of 
analytes with high reproducibility, miniaturised protocols and increased output. 
In spite of the advantages of ELISA and PCR, the multiplex immunoassay allows 
for a large number of analyses in a short amount of time through simultaneous 
measurement of expression of genes in a single sample by reducing time, labour 
and cost. The omics profiling using whole genome, epigenome, transcriptome, 
proteome and metabolome may also offer detailed information and aid person-
alised medicine [8]. Precision medicine is based on advanced omic technologies, 
such as next generation sequencing, protein and gene microarray, laser capture 
microdissection in the correlation of genomics, epigenomics, proteomics and 
metabolomics with the clinical phenotypes of the individual patient. The devel-
opment of multiplex genotyping technologies and high-throughput genomic 
profiling allows the analysis of the patient genome from peripheral blood or 
biopsy samples [9].
Assaying for soluble antigens and antibodies as biomarkers of various diseases 
has always been an invaluable diagnostic and research tool. Currently, ELISA has 
potentially replaced agglutination, complement fixation, precipitation and immu-
nodiffusion in diagnosis and research. The possibility of automation of the test 
procedure is one of the main reasons in transition from the classical serological tests 
to ELISA. Despite its advantages, ELISA is capable of measuring one analyte or a 
few analytes at a time, which may be a limiting factor where multiple markers need 
to be evaluated. Although the original idea of multiplexed assays involves antigen-
antibody interaction, a vast knowledge comes from planar DNA microarrays. The 
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chemical synthesis of oligonucleotides, DNA sequencing and PCR are major break-
through technologies which greatly accelerated the accumulation of genomic and 
transcriptomic data. These key technologies also enabled the construction of DNA 
microarrays with the aid of bioinformatics, optics and microfluidics [10]. Systems 
biology research demands a complete snapshot of measurable parameters possible 
at a time in order to analyse and describe biological systems. The DNA microarray 
fulfils the requirement in the detection of cellular changes such as genetic polymor-
phisms, mutations, methylation patterns and transcript abundancies. However, 
these features usually give an indirect assessment of the cellular physiology. A more 
concrete and detailed picture of cellular machinery may be depicted by means 
of high-throughput analysis of proteins and metabolites. The DNA microarray 
involves surface immobilisation of DNA probes with sequences deduced from either 
nucleic acid or protein database. It has always been an intricate task to fabricate 
high-throughput multiplexed protein arrays compared to DNA arrays since proteins 
are physicochemically more diverse, complicated and often fragile in nature. Today, 
60-plex cytokine measurement panels are available, in contrast to thousands of 
DNA probes in one planar microarray [10–14]. The real benefits of multiplexing 
assays may be achieved by miniaturisation of immunoassays. The real potential of 
microspot mediated analyte detection was discovered by Roger Ekins [6], in which 
the number of capture molecules can be attached onto a large macrospot surface 
far exceeding a tiny microspot surface. Consequently, macrospots consume analyte 
molecules in the sample to yield higher total signal intensity; even after all analyte 
molecules have been consumed, the available binding sites still remain on the 
assay surface. In contrast, decreasing spot size enhances the occupancy of capture 
molecules with analytes. Therefore, capture molecule concentration is directly 
related to assay surface area and total signal intensity and inversely related to signal 
density [15].
Multiplexed in situ tagging (MIST) is a reliable strategy which makes use of 
convertible DNA antibody barcoded arrays. It assays hundreds of molecular targets 
in a single cell, with high throughput and sensitivity. MIST technique was created to 
overcome the limitations of prevailing microfluidic-based methods [16]. One of the 
common limitations of conventional microfluidic-based single-cell protein assays 
was low multiplexity, which is often linked to fluorescence spectrum overlap, due 
to the phenotypically similar cell populations exhibiting a large degree of intrinsic 
heterogeneity [17]. Recently, technological advancements in single-cell proteomics 
have allowed highly multiplexed measurement of multiple parameters simultane-
ously by using barcoded microfluidic ELISAs and mass cytometry techniques 
[18]. It was achieved by integrating a multicolor, multicycle molecular profiling 
technique with barcoded microbead antibody arrays and a DNA-encoded antibody 
library [15, 16].
3. Planar and suspension multiplex immunoassays
The multiplex assays use immunoassay principles in which high-affinity capture 
ligands are immobilised in parallel assays. The systems use either antibodies or 
proteins/peptides as binding molecules to capture circulating proteins or autoanti-
bodies. The multiplex immunoassays are divided into two classes: planar assays and 
suspension microsphere assays. In planar assay, the capture ligands are immobilised 
on a two-dimensional support and the fluorescent or chemiluminescent signals 
identified. In suspension assay, the capture ligands are immobilised on colour- or 
size-coded microspheres, and flow cytometry is used to detect assay-specific 
fluorescent signals (Figure 1) [19]. Planar arrays can be produced in two formats, 
5Multiplex Technology for Biomarker Immunoassays
DOI: http://dx.doi.org/10.5772/intechopen.91730
either slide based or microtitre based. The slide-based format supports various 
layouts where repeated or individual assays composed of specific sets of antibod-
ies are printed robotically upon the activated slide surface. The microtitre-based 
immunoassays harbour antibodies within the wells of a standard protein-binding 
plate as in conventional ELISA. The suspension immunoassay employs thousands of 
micrometre-sized plastic microbeads infused with a chemiluminescent/fluorescent 
dye and a functionally activated surface, prior to linking with a specific capture 
antibody. The detection antibodies are individually labelled with a single chemilu-
minescent/fluorescent reporter added upon completion of incubation and washing 
stages. Each bead accommodates a ‘sandwich’ consisting of the captured target 
analyte and the cognate reporter-conjugated detection antibody. The bead analyte 
reporter constructs are subjected to analysis in a flow chamber bead separation in 
which the lasers excite the chemiluminescent/fluorescent reporters and emitted 
light is collected by a series of detectors for quantitative analysis (Figure 2) [1].
In the planar microarray format, the capture molecules are spotted on the modi-
fied glass surface to form a grid, and micrometric-sized beads may also be used 
as assay surfaces. A mixture of beads with a library of capture molecules is called 
‘bead array’ or ‘liquid array’. A suspension of the bead library is allowed to interact 
with the sample and reporter molecules [20]. Flow cytometry is used to measure 
the assay signals in the beads. Multiplex bead array assays (MBAA) offer multiple 
analyses at a time, but there may be discrepancies in measurements of certain 
cytokines by using ELISA or MBAA. In many experimental setups, it was not 
possible to test the same pair of capture and reporter antibodies in both tests which 
may originate from multiplexing itself. Possible cross-reactivity between the target 
analytes and other interfering substances present in the sample may cause matrix 
effect. Therefore, precaution is required in multiplexing assays that work perfectly 
in monoplex systems [15].
Figure 1. 
Planar and suspension multiplexed immunoassay formats. In planar assays, capture ligands are immobilised 
on a rigid two-dimensional support and probed with sample. In suspension assays, capture ligands are 
immobilised on colour- or size-coded microspheres. Assays are distinguished by coding attributes, and 
flow cytometry is used to detect assay-specific fluorescent signal (adapted and reproduced from [19], with 
permission).
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4. Multiplex immunoassays for autoimmune diseases (AD)
A substantial percentage of the population carries detectable levels of circulat-
ing autoantibodies without developing clinical symptoms. Autoantibodies are 
also present in the sera of patients with systemic autoimmune diseases, such as 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), etc. many years 
before clinical disease onset. The detection of antinuclear antibodies (ANA) has 
long been an important tool in the early diagnosis of autoimmune connective tissue 
diseases [21–25]. Antinuclear antibodies are detected in a substantial population, 
yet few individuals are diagnosed with the autoimmune disease, although some 
ANA-positive healthy individuals eventually develop clinical autoimmunity [26]. 
The correct use and interpretation of serologic testing for diagnosing autoimmune 
diseases present a challenge to clinicians for several reasons: (a) the sensitivity 
and specificity of laboratory tests for autoimmune disease and (b) detection of 
autoantibodies using different techniques such as indirect immunofluorescence 
(IF) or MBAA give different results. Multiplex microarray-based ELISA assays 
provide consistent results when compared with ELISA-based tests with the added 
advantage of reduced labour and the complete autoantibody profile in a single test. 
Autoantibody biomarkers assist in diagnosis and monitoring of disease activity, 
predicting disease onset, classifying disease subsets and defining prognosis. Despite 
various methods being used for autoantibody profiling, new techniques continue to 
be developed to facilitate diagnosis and therapeutic monitoring in connective tissue 
diseases [26, 27]. It is critical to evaluate new methods along with those being used 
in laboratories in order to assess their performance as well as to identify deficiencies 
of methods that are in current use such as methodology based on ELISA, western 
blot immunoassays, etc. [27].
Figure 2. 
Multiplex assays include planar-based assays and suspension-based assays. (A) Planar arrays (B) Suspension 
assay. Both assays us the serum sample extracted from blood as the starting point. (adapted and reproduced 
from [1], with permission from WILEY-VCH Verlag GmbH & Co).
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Immunoassays are generally not considered as multiplex assays even though 
double immunodiffusion or immunoprecipitation can detect many specific auto-
antibodies in a single run [28]. Multiplex technology is considered to be beneficial 
for the simultaneous detection of different autoantibodies related to autoimmune 
diseases. The autoantibody profiling of patients may be useful for determining 
the concentration of specific autoantibodies, which may display different trends 
over time, both for diagnosis and prognosis, e.g. celiac disease, anti-phospholipid 
syndrome (APS), etc. which are characterised by the presence of autoantibodies of 
different isotypes. Nowadays, multiplex technology has achieved high analytical 
accuracy and provides results comparable or superior to the manual and automated 
monoplex technology [29]. Multiplex autoantibody assays can detect many specific 
autoantibodies in a single run, whereas the traditional ELISA uses a single antigen to 
detect only a single autoantibody. Thus, in a multiplex assay, a combination of native 
antigens or antigenic peptides is used to detect many autoantibodies. The multiplex 
assays include line immunoassay (LIA), MBAA, and solid-phase antigen microarray 
(protein microarray). LIA is similar to the dot blot or western blot (immunoblot) 
in which a diluted serum is incubated with a strip that has several specific antigens 
in different areas on a strip. In MBAA, beads of different sizes and fluorochromes 
with different colours or intensities are coated with specific antigens for the detec-
tion of specific autoantibody. In antigen microarrays, different specific antigens are 
coated on a slide/membrane, and the strips, mixture of beads or slide/membrane 
with multiple antigens are incubated with the diluted serum, and many specific 
autoantibodies can be determined simultaneously. While new multiplex immunoas-
says have certain advantages over conventional assays, using them without complete 
understanding or validation against classic or standard assays may lead to concerns, 
confusions and conflicts in autoantibody immunoassays in clinical settings [28].
5. Conclusion
Although immunoanalytical techniques are established and advantageous over 
alternative screening analytical platforms, one of the challenges for immunoassays 
is multiplexing. The simultaneous on-site measurement of different substances 
from a single sample called multiplex testing has become increasingly important 
for in vitro quantification of pathological or toxicological samples. The multiplex 
assays have recently gained importance for clinical diagnostics, with emerging 
applications in the developing world. The multiplex assays have several advantages 
such as performing many reactions on the sample and the ability to provide more 
information from the sample in a fast and efficient manner. Hence, the technologi-
cal advancements in clinical sciences are helpful in the identification of analytes or 
biomolecules in pathological samples. While ELISA is still commonly used, many 
laboratories and organisations are moving towards multiplex immunoassays. The 
ELISA formats are able to accurately diagnose and characterise a single analyte; 
however, their amalgamation into multiplex immunoassays confers the prospects of 
simultaneous measurement of multiple analytes in a single sample, thereby mini-
mising cost, time and volume.
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